Nonwoven and elastomeric substrates having formulations disposed thereon, wherein the formulations have improved compatibility with the substrate, are disclosed herein. More particularly, the formulations can be applied on the substrates without compromising the elastomeric properties and overall integrity of the substrate. Laminated articles using one or more of the nonwoven and elastomeric substrates having the formulations disposed thereon are further disclosed.

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The present application relates to new HtrA inhibitors and use thereof. Additionally, the present application also relates to new peptides for inhibiting CagA and use thereof.

Rat attractant compositions attractive to the rat species Rattus norvegicus are disclosed, which compositions are constituted of compounds found in the headspace volatiles of male urine odor or female urine odor. Said compositions are respectively termed male pheromone blend (MPB) and comprises 2-heptanone, 4-heptanone, 3-ethyl-2-heptanone, 2-octanone, 2-nonanone, and 4-nonanone in a ratio of 10:100:10:1:1:10 respectively, or female pheromone blend (FPB) and comprises 2-methyl-butyric acid, 3-methyl-butyric acid, heptanal, hexanoic acid, 2-phenylacetaldehyde, nonanal, and decanal in a ratio of 20:20:10:30:5:20:10. Devices including the rat attractant compositions, and methods of using said rat attractant compositions, are also disclosed.

A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.

A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.

Disclosed herein are veterinary compositions including imidacloprid or an analogue thereof; a pyrethroid; a solvent selected from the group consisting of N-methyl pyrrolidone, N-ethyl pyrrolidone and mixtures thereof; and dimethyl sulfoxide. The veterinary compositions of the invention are useful in methods of controlling parasites on or within warm-blooded domesticated animals.

The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1,
R2-COO—[—CH(CH.sub.3)—COO].sub.n—R1   Formula 1
or a Na, K, Ca, Mg, Fe(II), Zn, NH.sub.4, or Cu(II) salt thereof,
a glycolylate of formula 2,
R2-COO—[—CH2-COO].sub.n-R1   Formula 2
or a Na, K, Ca, Mg, Fe(II), Zn, NH.sub.4, or Cu(II) salt thereof,
a lactate ester of formula 3,
HO—CH(CH.sub.3)—COO—R2   Formula 3
and/or a glycolic acid ester of formula 4,
HO—CH2—COO—R2   Formula 4 wherein R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The compound, which preferably is a lactylate or a Na, K, Ca, Mg, Fe(II), Zn, NH.sub.4, or Cu(II) salt thereof, is particularly useful in the treatment or prevention of Clostridia. An animal nutrition composition and a method for preventing or treating infections are also claimed.